IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
Idexx Laboratories (IDXX) Stock Moves -0.76%: What You Should Know
by Zacks Equity Research
Idexx Laboratories (IDXX) closed at $487.66 in the latest trading session, marking a -0.76% move from the prior day.
New Study Favors Masimo's (MASI) Pulse Oximetry to Screen CCHD
by Zacks Equity Research
The latest study highlights the efficacy of using Masimo's (MASI) SET pulse oximetry in screening CCHD in newborns.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients
by Zacks Equity Research
PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.
Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19
by Zacks Equity Research
Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.
Cooper Companies' (COO) Unit Assigns Vuzix M400 Smart Glasses
by Zacks Equity Research
Cooper Companies' (COO) unit assigns smart glasses to boost productivity in operations.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its critical care products.
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
IDEXX (IDXX) CAG Placement Grows Sequentially Amid COVID-19 Woes
by Zacks Equity Research
IDEXX's (IDXX) Global Reference Lab revenues are growing organically in the United States and in international markets.
Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA
by Zacks Equity Research
For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.
Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.
Encompass Health (EHC) Continues to Expand Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) plans to construct a hospital in Texas for offering improved rehabilitative services, which highlights its efforts to bolster presence in the state.
Masimo's (MASI) EMMA Favored by New Study for Children
by Zacks Equity Research
The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.
NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies
by Zacks Equity Research
NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine
by Zacks Equity Research
Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.
Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care
by Zacks Equity Research
Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Cardinal Health (CAH) Inks Deal to Divest Cordis Business
by Zacks Equity Research
Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about robust demand for Hill-Rom's (HRC) product as well as its solid first-quarter fiscal 2021 results.
IDEXX Laboratories (IDXX) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
IDEXX Laboratories (IDXX) has been struggling lately, but the selling pressure may be coming to an end soon